The Human Variable 

ME/CFS is a relapsing, multisystem condition characterized by immune disruption, neuroinflammation, autonomic dysfunction, and energy metabolism abnormalities. Trials should anchor in stabilization before pursuing cure.

Clinician Guide For MECFS Therapeutics: Built from CYNAERA Diagnostic Fingerprints™ + IACCI Terrain Logic + XR/CR Pharmacology Doctrine

For decades, ME/CFS has been treated as a monolith in research, despite overwhelming evidence of heterogeneity across patients. This failure to stratify has been a primary driver of trial collapse, clinical mismanagement, and neglect. The CYNAERA 25+ ME/CFS Phenotyping List integrates biological, environmental, and social terrain factors into a structured classification system.

Clinical trials for ME/CFS have consistently failed not because therapies were inherently ineffective, but because the system was never built for conditions like ME/CFS and related IACCs. FDA gold-standard trial design assumes predictable progression, uniform subtypes, and tolerance for interventions — none of which apply to ME/CFS The CYNAERA Thesis asserts that repurposed drugs can work for ME/CFS if trials account for post-exertional malaise (PEM),(MCAS), and POTS

The Va-IRI™ (Vaccination Immune Readiness Index) provides a structured 0–100 readiness score derived from common labs, symptom baselines, and patient function. Built on the STAIR Stable Method™ (Stabilization, Tolerance, And Immune Readiness), Va-IRI™ adapts low-and-slow principles pioneered by patients and refined through collaboration with leading researchers.

Using CYNAERA’s recalibrated US-CCUC™ prevalence models, which place the U.S. burden between 8.7 million (conservative) and 21.5 million (realistic), the annual economic impact rises to $243–817 billion.

Using CYNAERA’s US-CCUC™ model, we present a corrected demographic landscape grounded in published science, epidemiological data, and terrain-calibrated prevalence modeling. For the first time, undocumented immigrant populations and ancestral dietary biology are incorporated as visible drivers of disease prevalence. Our analysis demonstrates that half of Americans with ME/CFS are non-white, and that prevalence in certain groups is likely higher when adjusted for baseline into

Using CYNAERA’s US-CCUC™ (U.S. Chronic Condition Undercount Correction – Pediatric Edition) methodology, we estimate 1.5–3 million U.S. children and adolescents and 10–20 million globally meet ME/CFS criteria in 2025.

Using CYNAERA’s recalibrated tiered prevalence model, weighted for environmental exposure, access to paid sick leave, and diagnostic inequity, we estimate that around 14.4 million Americans currently meet the diagnostic criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

CYNAERA’s US-CCUC™ (Chronic Condition Undercount Correction – U.S.) model provides a corrected formula for estimating the real burden of ME/CFS. It builds on pre-pandemic cases, integrates the Long COVID surge, and corrects for the 80–90% of patients who were always there — but never diagnosed. Whether you lean on the cautious estimate of ~9.5 million Americans or the more realistic ~21.5 million, the message is the same: ME/CFS is a condition that rivals the scale of diabete

The Global-CCUC™ (Chronic Condition Undercount Correction – Global) model provides a recalibrated framework. By weighting diagnostic suppression, environmental terrain, social protections, clinical awareness, and pandemic burden, it reveals a truer picture: 94–127 million conservative cases and 220–290 million upper-bound cases worldwide.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating, multi-system neuroimmune disease on par with multiple sclerosis or congestive heart failure in severity, but for decades, it’s been sidelined by global health systems. Underdiagnosis, outdated clinical criteria, systemic bias, and institutional inertia have obscured its true scale. The result: tens of millions worldwide excluded from diagnosis, care, or recognition.